Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.880
+0.260 (9.92%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Protalix BioTherapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 232 | 138 | 130 | 69 | 38 | 118 | |
| Market Cap Growth | 29.69% | 6.60% | 87.08% | 83.20% | -68.02% | 143.47% | |
| Enterprise Value | 205 | 117 | 115 | 82 | 26 | 141 | |
| Last Close Price | 2.62 | 1.88 | 1.78 | 1.37 | 0.83 | 3.63 | |
| PE Ratio | 41.41 | 47.21 | 15.62 | - | - | - | |
| Forward PE | 19.72 | 3.94 | - | 60.89 | - | - | |
| PS Ratio | 3.66 | 2.59 | 1.98 | 1.46 | 0.99 | 1.88 | |
| PB Ratio | 3.98 | 3.20 | 3.87 | -6.52 | -6.28 | -4.38 | |
| P/TBV Ratio | 4.28 | 3.20 | 3.87 | - | - | - | |
| P/FCF Ratio | - | 18.73 | - | - | - | - | |
| P/OCF Ratio | - | 15.96 | - | - | - | - | |
| EV/Sales Ratio | 3.32 | 2.19 | 1.75 | 1.72 | 0.68 | 2.24 | |
| EV/EBITDA Ratio | 26.38 | 22.35 | 9.86 | - | - | 35.08 | |
| EV/EBIT Ratio | 32.23 | 29.80 | 10.98 | - | - | 51.93 | |
| EV/FCF Ratio | - | 15.79 | - | - | - | - | |
| Debt / Equity Ratio | 0.16 | 0.13 | 0.78 | -3.15 | -5.54 | -2.38 | |
| Debt / EBITDA Ratio | 0.85 | 0.81 | 2.00 | - | - | 11.94 | |
| Debt / FCF Ratio | - | 0.75 | - | - | - | - | |
| Net Debt / Equity Ratio | -0.40 | -0.68 | -0.55 | -1.06 | 0.91 | -0.96 | |
| Net Debt / EBITDA Ratio | -2.72 | -5.61 | -1.57 | -0.95 | 0.28 | 6.44 | |
| Net Debt / FCF Ratio | 1.81 | -3.96 | 7.41 | -0.44 | 0.47 | -0.97 | |
| Asset Turnover | 0.86 | 0.68 | 0.93 | 0.74 | 0.54 | 1.11 | |
| Inventory Turnover | 1.37 | 1.21 | 1.28 | 1.13 | 1.05 | 1.02 | |
| Quick Ratio | 2.00 | 1.49 | 1.11 | 0.84 | 1.29 | 0.48 | |
| Current Ratio | 3.03 | 2.35 | 1.54 | 1.38 | 1.86 | 0.64 | |
| Return on Equity (ROE) | 12.64% | 7.64% | 72.50% | - | - | - | |
| Return on Assets (ROA) | 5.53% | 3.10% | 9.32% | -12.57% | -18.06% | 2.99% | |
| Return on Invested Capital (ROIC) | 19.78% | 18.94% | 127.32% | - | - | - | |
| Return on Capital Employed (ROCE) | 10.60% | 8.20% | 26.90% | -55.70% | -50.50% | -14.60% | |
| Earnings Yield | 2.38% | 2.12% | 6.40% | -21.50% | -72.80% | -5.50% | |
| FCF Yield | -5.16% | 5.34% | -1.90% | -36.92% | -31.00% | -22.59% | |
| Buyback Yield / Dilution | -15.89% | 1.66% | -70.04% | -9.81% | -51.43% | -96.44% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.